newsfilter
← Latest News
GlobeNewswire·

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Bank of America Corporation (NYSE: BAC); Coastal Financial Corporation (NASDAQ: CCB); and Erasca, Inc. (NASDAQ: ERAS): Grabar Law Office is Investigating Claims on Your Behalf

AARDBACCCBERAS
  • Grabar Law Office is investigating potential securities law violations by Aardvark Therapeutics (AARD) regarding misleading statements about the safety of its drug candidate ARD-101 before \& after its February 13, 2025 IPO.
  • Aardvark's stock price allegedly dropped 56% following a February 27, 2026 announcement to pause the Phase 3 HERO trial due to cardiac observations, followed by a 32.1% decline after the FDA issued a full clinical hold on May 14, 2026.
  • The firm is investigating Bank of America (BAC) for breaches of fiduciary duty related to alleged failures in anti-money laundering controls, Bank Secrecy Act compliance, \& adherence to federal sanctions prior to a $1.21 billion Treasury penalty announced on October 13, 2026.
  • Bank of America admitted to willfully violating the Bank Secrecy Act by failing to implement adequate AML programs \& detecting over $5 billion in suspicious activity between January 1, 2018, \& July 1, 2025.
  • Grabar Law Office is investigating Coastal Financial Corporation (CCB) for allegedly concealing the deterioration of a $500 million loan portfolio within its CCBX business, which led to a surprise $42.1 million GAAP net loss reported on July 30, 2026.
  • Former executives of Coastal Financial Corporation are alleged to have sold approximately $15.8 million in stock before the company disclosed the significant credit losses associated with the CCBX partner portfolio.
  • The firm is investigating Erasca, Inc. (ERAS) for misleading statements concerning its drug candidate ERAS-0015, including improper comparisons to a competitor \& failure to disclose patent risks \& a patient death linked to pneumonitis.
  • Erasca's share price declined substantially after disclosures on April 27, 2026, revealed patent infringement allegations from Revolution Medicines, admitted limitations in clinical comparisons, \& a fatal adverse event in a Phase 1 trial.
  • Shareholders in all four companies may be eligible to seek corporate reforms, restitution of funds to the companies, \& incentive awards through a shareholder governance or derivative action at no cost.